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Summary.-An antigen common to human sarcomas, S3, has been further character-
ized. It is antigenically distinct from human blood-group substances A and B and
from heterophile antigens such as Forssman, infectious mononucleosis and serum
sickness antigens. Whilst S3 antigen preparations may contain small amounts of
CEA and AFP there is no correlation between S3 antigen and the presence or amount
of these known tumour-associated substances. S3 antibody can be fully absorbed
with guinea-pig kidney but not boiled beef or SRBC. S3, therefore, is a heterophile
substance which has not previously been identified. A seroepidemiological survey
confirms that S3-antibody prevalence is significantly increased in persons with a
wide variety of malignant disease, as well as in family members of patients with
sarcoma.
WE HAVE PREVIOUSLY DETECTED (Sethi
& Hirshaut, 1976) a tumour-associated
antigen common to human sarcomas, using
a complement-fixation assay. The preval-
ence of antibody to this antigen, S3, is
markedly increased in persons with sarc-
oma, and to a lesser extent in patients
with a wide variety ofother solid tumours.
When a group of patients with sarcoma
was followed through surgery and their
antibody levels to S3 determined before
and after operation, sharp increases in
antibody titres were observed after the
removal of the tumour. Titres remained
high in those with residual disease but
gradually fell to undetectable levels in
patients whose malignancy had been com-
pletely excised. These initial data (Sethi
et al., 1978) suggest that the determination
ofchanges in S3-antibody levels in sarcoma
patients and others with malignancy
might be of prognostic value.
This paper reports the results of addi-
tional studies to characterize the 83 anti-
gen. Immunological techniques have been
used to determine the heterogeneity of 83
preparations from different sources, and
to discover whether S3 is related to pre-
viously identified antigens in benign and
malignant tissues. Seroepidemiological
studies have been completed to delineate
more fully the distribution of S3 antibody.
MIATERIALS AND METHODS
Cell cultivation -Human sarcoma cells
propagated in tissue culture are the source of
83 antigen. Details ofprocedures used for the
establishment of sarcoma cell lines have been
presented elsewhere (Sethi et al., 1977).
Cultured cells were maintained at 37TC in
RPMI 1640 medium supplemented with 20%
inactivated and filtered foetal calf serum.
They were transferred and fed every 2-3
weeks. Cell lines were also checked periodic-
ally for mycoplasma by the method of Fogh
et al. (1967). Those used to prepare S3 were
established to be free of such contamination.
Preparation of S3 antigen.-Test antigen
was obtained from cultured cells harvested
with a rubber policeman. Proteolytic enzymes
were not used for cell dispersion. After wash-
ing the cells with phosphate-buffered saline
(PBS) at pH 7*4, a 20% cell suspension was
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prepared in PBS. Cells were then frozen and
thawed x 3 in liquid N2 and a 37°C water bath
respectively. Cell membranes were addition-
ally disrupted by sonication (Biosonic IV;
VWR Scientific. San Francisco, California)
for 2-3 min (10 sec/ml) in 1-min bursts. The
crude suspension wAithout further centrifu-
gation or filtration was the antigen source.
This material wNas dispensed for storage into
1-ml polypropylene tubes kept in a freezer at
-70°C.
Complement-fixationl assay.-In the test for
S3, a standard microcomplement fixation
method was used (Sever, 1962). All dilutions
were made with veronal buffered saline
(VBS) pH 7-4. Pooled, titred human cord
serum was the complement source. All sera
assayed for 83 antibody were stored at - 70°C
before use. For testing, sera were diluted with
an equal volume of VBS, inactivated at 560C
for 30 min. and then checked for anti-
complementary activity. Amboceptor (Difco
Laboratories Inc., Detroit. Mich.) w%ras pre-
titred and freshly diluted for incubation with
SRBC. Antigen titres were determined by a
checkerboard titration, using a standard high-
titred serum from a patient wNith osteogenic
sarcoma as the source of S3 antibody. Each
experiment included controls for serum
antigen, complement, and sheep red blood
cells (SRBC). The results were recorded on a
0-4+ scale corresponding to the size of the
red-cell button and the amount of comple-
ment fixed.
To conduct the complement-fixation test,
0-025 ml VBS was delivered to each wNell in
the plate. Serum was then added to the first
horizontal row of Mwells, and serial 2-fold
dilutions were made in a vertical direction
with 0-025ml diluting loops. Every serum
sample was diluted in du,plicate using ad-
jacent vertical rows of wells. Then 2 units of
antigen were placed in alternate vertical rowrs
of wells and the remaining wells received a
similar volume of VBS. Finally, two 100%-
haemolytic units of complement were added
to all wells, and the plates were incubated
overnight in a plastic bag at 4°C. The next
day, 0-05ml sensitized SRBC were added to
each well. The haemolytic system was a 2%
suspension of 4-6-week-old washed SRBC.
SRBC were sensitized by incubation with an
equal volume of 1:800 diluted rabbit anti-
serum against SRBC (amboceptor) at 37°C
for 30 min. The whole plate was again incu-
bated at 37°C for 1 h with gentle intermittent
shaking. Finally each plate was centrifuged
for 5 mnim- at 1000 rev/min and readings were
taken. Sera giving a 2+ reaction or greater at
a dilution of 1: 4 or above, and free of anti-
complementary activity, were considered
positive for S3 antibody.
Absorption procedures. Sera to be studied
were inactivated at 56°C for 30 min. They
were then diluted A-ith VBS to twice their
limiting positive dilution. One aliquot re-
mained unabsorbed while other aliquots A-ere
mixed -with an equal volume of absorbing
material. All samples were gently shaken for
3 min and then stored at 4°C overnight. The
next day, after centrifugation at 2000 rev/
min for 15 min, supernatants were removed
by pipette and tested against a standard S3
preparation in a complement-fixation assay.
ITnabsorbed serum wAas run as a control with
each assay. Absorbants included S3 antigen
preparation, boiled beef (BB), guinea-pig
kidney (GPK), sheep red blood cells (SRBC),
Type A and B RBC an-d carcinoembryonic
antigen (CEA).
Otherassays. CEAand a-fetoprotein (AFP)
levels -were measured by radioimmunoassay
(RIA) using techniques previously described
(Hansen et al., 1971: W\aldman & Mclntire,
1972).
These tests wvere performed respectively in
the laboratories of Drs Morton Sch-wartz and
Thomas Waldmann. Anti-Epstein-Barr Virus
(EBV) viral capsid antigen (VCA) titres were
performed by the method of Hirshaut et al.
(1969).
RESULTS
The cell lines used for S3 preparations
are presented in Table I. To compare S3
TABLE I. Cell
Diagnosis
Osteosarcoma
Schiwanoma
Liposarcoma
Rhabdosarcoma
Clhondrosarcoma
Fibrosarcoma
Leiomyosarcoma
Liposarcoma
Synovial sarcoma
Spindlle-cell sarcoma
Osteosarcoma
Liposarcoma
lines used to prepare S3
antigen
Patient
WR
CR
,JB
GK
AIB
JR
JL
SH
CH
MIL
PR
FAM
Cell
linle
ROS-23
RSS-25
BLS-50
KRS-70
BCS-72
RFS-75
LMAIS-76
HLS-80
CS-145
LSCS-147
ROS-151
MLS-164
S3
antigen
±
+
+
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TABLE II. Cross-rea
S3 prepa
Serum (lonor E
Osteosarcoma
Neurogenic sarcoma
Alyxoliposarcoma
Fibrous histiocytoma
Liposarcoma
Fibrosarcoma
AIyxoliposaIrcoma
Rhabdomyosarcoma
Mtyxoliposarcoma
Liposarcoma
Liposarcoma
antigen preparation fi
and 5 53- sera were te
derived from cell lin
RFS-75. As seen in I
sera showed an identi
the 3 different 83 pre
titres against S3 from
one 2-fold dilution
absorption experimen
prepared from cell
LSCS-147 (Table III
positive antisera to tl
parations was remov
with either antigen. A
ducted at twice the
each test serum with n
TABLE I1I. Cro88-c
preparo
Serum (lonol-
Osteosarcoma
Spindle-cell sareorna
Normal
ctions (titres) against ing after absorption. The restults showed
zrations the 2 antigens to be fully cross-reactive.
Antigen preparations To confirm the anti-83 specificity of the
absorptions, serum samples before and
3CS-72 LMS-76 RFS-75 after absorption with an S3- and 2 S3+
1/16 1/32 1/32 preparations were titred for anti-S3 and
1/32 1/64 1/64 anti-EBV-VCA levels. The data are
1/32 1/64 1/64 summarized in Table IV. ROS-151, an S3-
1/32 1/64 1/64 preparation, did not absorb any anti-S3
1/32 1/64 1/64 activity from the sera, but MLS-164 and
1/32 1/64 1/64 LSCS-147 absorbed anti-S3 activity com-
= - = pletely. No changes in the anti-EBV-V7CA
titres were seen when the absorptions were
conducted with either S3+ or the S3-
rom 3 sources, 6 83+ preparation.
zsted against antigen The association of 83 with non-tulmour-
es BCS-72, LMS-76, associated blood groups or heterophile
7able II, each of the antigens was sttudied by absorbing 8 S3+
ical reaction against and 4 S3- sera with SRBC, GPK, BB and
parations. However, human blood cells of Types A and B. The
BCS-72 tended to be data obtained are presented in Table V;.
lower. In a cross- None ofthe reactivity of positive sera was
it, using S3 antigen absorbed with SRBC, BB and Type A and
lines CS-145 and B human RBC. All the activity, however,
L) all reactivity of was removed from the same sera after
he 2 S3 antigen pre- absorption with GPK.
red after absorption S3 was distinguished from nCEA by
bsorptions were con- determination of CEA levels in + ve and
limiting dilution of -ve antigen preparations and in + ve and
io reactivity remain- -ve sera. Small quantities of CEA were
present in 4 of the 5 83 antigen prepara-
tbsorption with S3 tions tested. There was no correlation,
zttions however, as evident in Table VI, between
Cross the presence of CEA and S3 reactivity. Titres absorptioin Both S3+ and 83- sera were found to con-
tain measurable CEA (Table VI). Absorp- v5 LSCS- CS- LSCS- tion of 2 53 antibody+ sera with purified
.64 1:64 /+* /+ CEA caused no loss of anti-83 reactivity.
32 1:32 /+ /± AFP levels in S3+ antigen preparations
-/- -/- and antisera were also assayed. Results
d at twice limiting dilti- are shown in Table VII. Again o0W levels
of AFP were found in antigen and anti-
c
1:
1:
* Post/1're. Sera absorbe4
tion.
TABLE IV. Summary of absorptions for anti-S3 specifcity with S3+ and S3- antigen
preparations
Anti-S3 titres on absorption Anti-EBV-VCA titres oIn absol-ptioII
Un- ROS-151 MLS-164 LSCS-147 Un- ROS-151 ALS-164 LSCS-147
absorbed (S3-) (S3+) (S3+) absorbed (S3- ) (S3+) (S,3+)
1:64 1:64 - 1:320 1:640 1:32() 1:320
1:32 1:32 1:320 1:320 1:320 1:320
1:8 1:8 N.D. N.D. N.). N.L). N.D.
Serum
donor
Osteosarcoma
Liposarcoma
Osteosarcoma
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TABLE V.-Summary ofS3 absorption studies
Absorption materialt
A
GPK
-I+
-I+
-I+
-I+
-I+
-I+
-I+
_-I_
_-I_
BB
+I+
+I+
+I+
+I+
+I+
+I+
+I+
+I+
_-I_
_-I_
_-I_
SRBC
+I+
_-I_
+I+
+I+
+I+
+I+
+I+
+I+
+I+
_-I_
_-I_
A
+I+
+I+
+I+
+I+
+I+
N.T.
N.T.
N.T.
N.T.
N.T.
N.T.
B
+I+
+I+
+I+
+I+
+I+
N.T.
N.T.
N.T.
N.T.
N.T.
N.T.
S3
-I+
NI-_ N.T.
-I+
N.T.
-I+
-1+
-I+ -I+
_-I_
_-I_
* Post/Pre.
t Absorptions at twice limiting dilution.
body samples but there was no correlation
between AFP levels and quantity of S3
antigen or antibody in the same material.
To confirm previous observations about
the seroepidemiology of S3 antibody, the
number of patients studied has been in-
creased, and now includes 378 with a
variety of malignancies and 54 controls
(Table VIII). Patients with sarcoma con-
TABLE VI.-CEA analysis of S3 prepara-
tions and serafrom sarcoma patients
Antigen
preparation
ROS-23
RSS-25
BLS-50
KRS-70
BCS-72
Serum donor
Liposarcoma
Liposarcoma
Rhabdomyosarcoma
Liposarcoma
Serum donor
Fibrosarcoma
Myxoliposarcoma
Histiocytoma
S3 antigen CEA (ng/ml)
1-0
- 10-0
0.0
+ 1-0
+ 17-0
Anti-S3 titre CEA (ng/ml)
7 0
11-0
i 1:64 12-0
1:64 19-0
Absorption with CEA
+I+*
+I+
* Post/Pre. Sera absorbed at twice limiting
dilution.
tinue to have the highest prevalence of S3
antibody. Increased prevalence is also
found in those with a variety of carcin-
omas and to a lesser degree in persons with
lymphoproliferative neoplasms. Only 4 of
the 54 normal subjects tested (7%) were
found to have circulating levels of anti-
body to S3, whereas sarcoma family mem-
bers have higher prevalence (40%).
TABLE VII.-AFP analysis of S3 prepara-
tions and serafrom sarcoma patients
Antigen
preparation
ROS-23
RSS-25
BLS-50
KRS-70
BCS-72
HLS-80
Serum donor
Liposarcoma
Liposarcoma
Rhabdomyosarcoma
Liposarcoma
S3 antigen
Anti-S3 titres
1:64
1: 64
AFP (ng/ml)
21-0
35*0
14-0
19-5
52-0
29-0
AFP (ng/ml)
19-0
20-0
14-0
14-0
TABLE VIII.-Distribution of S3 antibody
in patients with malignant neoplasm
Diagnosis Tested + % +
Sarcoma 43 32 74
Sarcoma family members 20 8 40
Carcinoma
Breast 28 15 53
Head and neck 25 13 52
Lung 27 14 52
Colon 30 14 47
Ovary 31 13 42
Melanoma 29 12 41
Prostate 22 7 32
Lymphoproliferative malignancies
Lymphosarcoma 29 11 38
Reticulum-cell sarcoma 27 9 33
Hodgkin's disease 32 10 31
Acute lymphocytic leukaemia 19 4 21
Normal 54 4 7
Anti-S3
activity
+
+
+
+
+
Serum donor
Rhabdomyosarcoma
Fibrosarcoma
Osteosarcoma
Liposarcoma
Osteosarcoma
Fibrosarcoma
Neurogenic sarcoma
Myxoliposarcoma
Rhabdosarcoma
Myxoliposarcoma
Liposarcoma
Liposarcoma
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DISCUSSION
Characterization ofS3 requires prepara-
tion of large quantities of antigen. Un-
fortunately, it is difficult to predict
whether a given passage of a human sar-
coma cell line will contain detectable S3
(Sethi & Hirshaut, 1978). This places
practical limits on the size of any single
culture passage prepared from different
passages of the same lines and from
different lines. It is therefore particularly
important that S3 antigen prepared from
several cell lines has been found to be
immunologically identical.
The complete absorption of S3 antibody
from test sera by GPK, but not SRBC or
BB, establishes S3 as a new heterophile
antigen distinct from the well known
heterophile substances associated with
SRBC, such as Forssman, infectious mono-
nucleosis and serum-sickness antigens.
The availability of a second source of S3,
GPK, will also be of assistance in charac-
terization studies. This may be particu-
larly important for biochemical isolation
which requires large volumes of starting
materials.
Heterophile antigens related to SRBC
(particularly Forssman antigen) may be
expressed more frequently by malignant
than normal tissues (Milgrom et al., 1973).
Increased heterophile antibody titres have
been reported in patients with Hodgkin's
disease (Kasukawa et al., 1976), sarcoma
(Feit et al., 1977) and other neoplastic
diseases (Southam et al., 1951). They are
decreased in carcinoma of the lung
(Kitamura et al., 1979). Another sarcoma
antigen discovered in this laboratory, Si
(Hirshaut et al., 1974), has also recently
been shown to be a heterophile substance
not found on SRBC. Si antibody preval-
ence is consistently higher in patients with
malignancy. We have now identified S3
antibody as another heterophile antibody
the prevalence of which is increased in
cancer patients.
The presence of CEA and AFP in some
S3 antigen preparations and S3 antisera
makes it mandatory to distinguish these
from S3. The lack of any relationship
between the presence of these two well
characterized tumour antigens and S3
antigen or antibody titres makes it un-
likely that there is any cross-reactivity.
For CEA this is confirmed by the inability
of purified CEA to absorb S3 antibody.
While the highest prevalence of S3 anti-
body has so far been found in patients
with sarcoma, the expanded seroepidemi-
ologic investigation confirms that patients
with a wide variety of malignant diseases
have an increased prevalence of antibody
to S3, as do family members of those with
sarcoma. This lack of specificity precludes
the use of an S3 assay for diagnosis. How-
ever, the increased prevalence of antibody
in persons with so many different neo-
plastic diseases implies that changes in S3
antibody levels may be ofprognostic value
in patients with a variety of malignant
conditions.
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